Baxter Bros Inc. Has $5.60 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Baxter Bros Inc. lessened its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 12.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 77,236 shares of the medical research company's stock after selling 10,588 shares during the quarter. Baxter Bros Inc.'s holdings in Edwards Lifesciences were worth $5,598,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of EW. Harbor Investment Advisory LLC increased its stake in Edwards Lifesciences by 26.3% during the 1st quarter. Harbor Investment Advisory LLC now owns 22,507 shares of the medical research company's stock worth $1,631,000 after buying an additional 4,682 shares during the period. Inspirion Wealth Advisors LLC grew its stake in shares of Edwards Lifesciences by 4.3% during the first quarter. Inspirion Wealth Advisors LLC now owns 11,763 shares of the medical research company's stock valued at $853,000 after acquiring an additional 488 shares in the last quarter. Czech National Bank increased its position in shares of Edwards Lifesciences by 5.9% during the first quarter. Czech National Bank now owns 135,468 shares of the medical research company's stock worth $9,819,000 after acquiring an additional 7,587 shares during the last quarter. Legacy Wealth Asset Management LLC boosted its holdings in Edwards Lifesciences by 5.8% in the first quarter. Legacy Wealth Asset Management LLC now owns 21,960 shares of the medical research company's stock valued at $1,592,000 after purchasing an additional 1,207 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in Edwards Lifesciences by 4.1% during the 1st quarter. Rhumbline Advisers now owns 1,130,154 shares of the medical research company's stock valued at $81,913,000 after purchasing an additional 44,249 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Activity

In other news, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. This represents a 9.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This represents a 1.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 59,012 shares of company stock worth $4,224,717. 1.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Robert W. Baird increased their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. Citigroup reissued a "buy" rating and set a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research report on Monday. Finally, Evercore ISI lowered their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $80.20.

Edwards Lifesciences Stock Performance

Shares of EW traded down $0.21 during trading hours on Friday, reaching $77.56. 2,633,909 shares of the company's stock traded hands, compared to its average volume of 5,207,964. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25. The business's fifty day simple moving average is $73.98 and its two-hundred day simple moving average is $72.75. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market capitalization of $45.50 billion, a price-to-earnings ratio of 11.13, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. The firm had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Edwards Lifesciences's quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $0.66 EPS. Analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.